Thiogenesis Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
A Study to Assess TTI-0102 vs Placebo in MELAS Patients
Phase 2
Recruiting
- Conditions
- MELAS SyndromeMitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Thiogenesis Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06644534
- Locations
- 🇫🇷
Angers University Hospital Center (CHU Angers), Angers, France
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
Phase 2
Withdrawn
- Conditions
- COVID-19 Acute Respiratory Distress SyndromeCOVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Thiogenesis Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05212662
© Copyright 2025. All Rights Reserved by MedPath